Evidence map›Paper›PMID 39406931›Full record

ArticleLeukemia2025

Anagrelide and idarubicin combination induces GSDME-mediated pyroptosis as a potential therapy for high-PDE3A acute myeloid leukemia.

Chenwei Yang, Yixin Hu, Li Gao, Zhiheng Li, Yongping Zhang, Ran Zhuo, Yayun Du, Hu Liu, Qi Ji, Minyuan Liu and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in Leukemia, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Chenwei Yang *Department of Pediatric Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, 215000, China.ORCID http://orcid.org/0009-0008-5326-7274
Yixin Hu *Department of Pediatric Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, 215000, China.
Li Gao *Department of Pediatric Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, 215000, China.
Zhiheng Li *Institution of Pediatric Research, Children's Hospital of Soochow University, Suzhou, 215000, China.
Yongping ZhangDepartment of Pediatric Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, 215000, China.
Ran ZhuoDepartment of Pediatric Surgery, Children's Hospital of Soochow University, Suzhou, 215000, China.
Yayun DuState Key Laboratory of Common Mechanism Research for Major Diseases and Key Laboratory of Synthetic Biology Regulatory Elements, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, 215123, Jiangsu, China.
Hu LiuDepartment of Pediatric Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, 215000, China.
Qi JiDepartment of Pediatric Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, 215000, China.
Minyuan LiuDepartment of Pediatric Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, 215000, China.
Jian PanInstitution of Pediatric Research, Children's Hospital of Soochow University, Suzhou, 215000, China.ORCID http://orcid.org/0000-0002-0292-5141
Jun LuDepartment of Pediatric Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, 215000, China.
Peifang XiaoDepartment of Pediatric Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, 215000, China.
Yuanyuan TianInstitution of Pediatric Research, Children's Hospital of Soochow University, Suzhou, 215000, China. yuanyuan.tian18@yahoo.com.
Sudan HeState Key Laboratory of Common Mechanism Research for Major Diseases and Key Laboratory of Synthetic Biology Regulatory Elements, Suzhou Institute of Systems Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Suzhou, 215123, Jiangsu, China. hesd@ism.pumc.edu.cn.ORCID http://orcid.org/0000-0002-0846-1210
Jing LingDepartment of Transfusion Medicine, Children's Hospital of Soochow University, Suzhou, 215000, China. lingjing@suda.edu.cn.ORCID http://orcid.org/0000-0003-3929-140X
Shaoyan HuDepartment of Pediatric Hematology and Oncology, Children's Hospital of Soochow University, Suzhou, 215000, China. hushaoyan@suda.edu.cn.ORCID http://orcid.org/0000-0002-3386-6957

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is an invasive hematopoietic malignancy requiring novel treatment strategies. In this study, we identified phosphodiesterase 3 A (PDE3A) as a potential new target for drug repositioning in AML. PDE3A was preferentially overexpressed in AML cells than in normal cells, and high expression of PDE3A was correlated with lower event-free survival (EFS) in de novo AML patients. The PDE3A inhibitor anagrelide (ANA) profoundly suppresses the proliferation of high PDE3A-expressing AML cells while exhibiting minimal impact on those with low PDE3A expression. Moreover, synergistic effect of ANA with other chemotherapeutic drugs in high PDE3A expression AML cells was observed. The ANA-idarubicin (IDA) combination showed the most remarkable synergistic effect among all ANA-chemotherapeutic drugs commonly used in AML cell line models. Mechanistically, the synergy between ANA and IDA inhibited the survival of PDE3A

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCyclic Nucleotide Phosphodiesterases, Type 3IdarubicinLeukemia, Myeloid, AcutePyroptosisAnimalsCell Line, TumorCell ProliferationDrug SynergismFemaleHumansMiceTumor Cells, CulturedXenograft Model Antitumor AssaysCyclic Nucleotide Phosphodiesterases, Type 3IdarubicinPDE3A protein, human

Identifiers

PMID39406931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.